



**Program Announcement for the Defense Health Agency**

# **Peer Reviewed Medical Research Program Platform Clinical Translation Award**

Funding Opportunity Number: HT942526PRMRPPCTA

Pre-Application Due: July 23, 2026

Application Due: September 22, 2026

***This program announcement must be read in conjunction with the General Application Instructions, version [CD26\\_01](#).***

# Content

	<b>Before You Begin</b>	<b>3</b>
①	<b>Basic Information</b> Summarizes the <u>funding opportunity</u> , <u>funding details</u> , <u>submission deadlines and review dates</u>	<b>4</b>
②	<b>Eligibility</b> Details eligibility factors for the <u>applicant organization</u> and <u>Principal Investigator</u>	<b>5</b>
③	<b>Program Description</b> Describes the <u>program mission</u> and <u>intent</u> of the Platform Clinical Translation Award; provides <u>key award information</u> and <u>considerations</u> ; and outlines <u>funding details</u>	<b>6</b>
④	<b>Application Contents</b> Presents the two-step <u>application process</u> and instructions for preparing a <u>pre-application</u> and <u>full application</u>	<b>23</b>
⑤	<b>Submission Requirements</b> Provides <u>locations for application packages</u> , instructions for submitting <u>pre-applications</u> and <u>full applications</u> , and describes <u>application verification</u>	<b>38</b>
⑥	<b>Application Review Information</b> Outlines the processes for application <u>compliance review</u> , <u>pre-application</u> and <u>full application</u> selection/notification, and <u>risk assessment</u> . Also, details the review criteria for <u>pre-application screening</u> and both tiers of the CDMRP application review process – <u>Peer Review</u> and <u>Programmatic Review</u>	<b>41</b>
⑦	<b>Federal Award Notices</b> Outlines what a successful applicant can expect <u>if recommended for funding</u>	<b>49</b>
⑧	<b>Post-Award Requirements</b> References <u>policy requirements</u> for funded research; outlines <u>reporting requirements</u> and restrictions related to <u>Principal Investigator changes</u> and <u>institutional award transfers</u>	<b>50</b>
⑨	<b>Other Information</b> Outlines criteria for administrative actions including application <u>rejection</u> , <u>modification</u> , <u>withdrawal</u> and <u>withhold</u>	<b>52</b>
	<b>Appendix 1</b> Includes a checklist for all full application components to facilitate application submission	<b>54</b>
	<b>Appendix 2</b> Acronym List	<b>56</b>

## Before You Begin

- **Active [SAM.gov](#), [eBRAP.org](#) and [Grants.gov](#) registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process [FAQ](#), a [Guide for Intragovernmental & Intramural Applicants](#) and a [CDMRP Video Series](#) detailing the application process.

## Who to Contact for Support

### eBRAP Help Desk

301-682-5507  
[help@eBRAP.org](mailto:help@eBRAP.org)

*Questions regarding  
funding opportunity submission  
requirements,  
as well as technical assistance  
related to pre-application or  
intramural application submission.*

### Grants.gov Support Center

800-518-4726  
International: 1-606-545-5035  
[support@grants.gov](mailto:support@grants.gov)

*Questions regarding  
Grants.gov registration  
and Workspace.*

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click  to be taken to additional guidance and instructions within the General Application Instructions (GAI).

## Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)  
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

# 1. Basic Information About the Funding Opportunity

**Summary:** The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Platform Clinical Translation Award supports the translational development and/or early-phase clinical trials for broadly applicable clinical technologies that will address urgent and complex needs related to two congressionally directed FY26 PRMRP topic areas. The platform product in development should address one of the FY26 PRMRP portfolio-specific strategic goals and address the health care needs of military Service Members, Veterans and their Families.

### Distinctive Features:

- **Allows for multiple Principal Investigators (PIs).** The proposed experiments may represent a single project led by a single PI, or it may consist of partnerships between principal investigators that will occur synergistically to advance a platform product. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. Up to two additional PIs can be identified as Partnering PIs. If recommended for funding, each PI will be named on separate awards to the recipient organization(s).
- **Requires a PI-convened external advisory board with patient advocate participation.** The patient advocate must be a person living with, or a family member or caretaker of someone with, a disease or condition addressed in one of the applicant-selected congressionally directed FY26 PRMRP topic areas.

**Funding Details:** The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly \$30M to fund approximately two Platform Clinical Translation Award applications with total cost caps of \$15M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with a maximum of \$8M in FY26, with the remaining budget to be funded out of future fiscal years depending upon meeting performance-based milestones and availability of future funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

### Submission and Review Dates and Times

- **Pre-Application (Preproposal) Submission Deadline:** 5:00 p.m. Eastern Time (ET), July 23, 2026
- **Invitation to Submit an Application:** August 24, 2026
- **Application Submission Deadline:** 11:59 p.m. ET, September 22, 2026
- **End of Application Verification Period:** 5:00 p.m. ET, September 30, 2026
- **Peer Review:** November/December 2026
- **Programmatic Review:** February/March 2027

**Announcement Type:** Initial

**Funding Opportunity Number:** HT942526PRMRPPCTA

**Assistance Listing Number:** 12.420

## Section Shortcuts

Basic Information | [Eligibility](#) | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

## 2. Eligibility Information

### 2.1. Eligible Applicants

#### 2.1.1. Organization

[Extramural](#) and [intramural U.S. Department of War \(DOW\)](#) organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities.***

#### 2.1.2. Principal Investigator

Independent investigators (e.g., Assistant Professor, Senior Scientist, Principal Scientist, Research Director, or equivalent) may be named by the organization as and initiating or partnering Principal Investigator (PI) on the application.

Each investigator may be named on only one FY26 PRMRP application as Initiating PI. If more than one pre-application submitted to the FY26 PRMRP names the same Initiating PI, the first submission will be accepted, and subsequent submissions will be administratively withdrawn.

Independent investigators affiliated with an eligible organization are eligible to be named PI on the application, regardless of ethnicity, nationality or citizenship status.

### 2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

### 2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the GAI for additional [recipient qualification requirements](#).

## Section Shortcuts


Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### 3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the Peer Reviewed Medical Research Program (PRMRP). The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the PRMRP in 1999 to support medical research projects of clear scientific merit and direct relevance to military health. Appropriations for the PRMRP from FY99 through FY25 totaled \$4.34 billion. The FY26 appropriation is \$370 million.

#### FY26 PRMRP Research Development Pipeline

To address the congressionally directed FY26 PRMRP topic areas in a bench-to-bedside fashion, the FY26 PRMRP award mechanisms are aligned to different phases of the research development pipeline illustrated below.



The **Use-Inspired Basic Research** phase represents novel, exploratory research aimed at generating preliminary data and/or preclinical research that is ready for validation through expansion, replication, or comparative studies. While projects may be aiming to understand fundamental physiological phenomena, “basic research,” they should be driven by a specific clinical need and potential application, “use-inspired.” Applicants seeking support for research aligning to the Use-Inspired Basic Research phase may consider:

- FY26 PRMRP Discovery Award** (HT942526PRMRPDA) for novel, high-risk, high reward research projects with the potential to yield high-impact findings and new avenues of investigation. Preliminary data is not allowed.

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **FY26 PRMRP Research Advancement Award** (HT942526PRMRPRAA) for building upon existing preliminary data to validate a concept.

The **Translational Research** phase seeks to transition scientific data towards treatment, diagnostic and/or preventive strategies. Research projects are expected to have significant near-term impact on patients' lives. Examples of projects in the translational phase include product/device development and clinical translation of concepts previously validated through expansion, replication or comparative studies. Applicants seeking support for research aligning to the Translational Research phase may consider:

- **FY26 PRMRP Impact Award** (HT942526PRMRPIPA) for mature research projects that are ready to translate ideas into solutions. Initial product discovery, development, and optimization are supported.
- **FY26 PRMRP Technology/Therapeutic Development Award** (HT942526PRMRPTTDA) for finalizing preclinical development of tangible products (drugs or biologics), knowledge-based products and/or devices. The research outcome should be a regulatory filing or translation of findings into clinical practice, as applicable.

The **Translational to Clinical Transition** phase represents the final stages of product development with early, phase 0/1, or equivalent, clinical trials. Products may include both knowledge and tangible items that will be used to impact patient care.

- **FY26 PRMRP Platform Clinical Translation Award** (HT942526PRMRPPCTA) for finalizing preclinical development, conducting clinical validation studies, and/or conducting first in human clinical trials for a platform product with the potential to impact clinical care for two or more FY26 PRMRP topic areas.

The **Clinical Research** phase represents small- and large-scale confirmatory trials and/or applied clinical research that will revolutionize the clinical management of the diseases and conditions assigned to the program as topic areas. Applicants seeking support for trials and studies aligned to the Clinical Research phase may consider:

- **FY26 PRMRP Lifestyle and Applied Health Research Award** (HT942526PRMRPLAHRA) for clinical trials focused on efficacy of non-pharmacological interventions or noninvasive devices or clinical research to examine the impact of prevention, diagnostic, treatment or health care delivery approaches on health outcomes. Animal research is not allowed.
- **FY26 PRMRP Clinical Trial Award** (HT942526PRMRPCTA) for projects to determine the safety or efficacy outcomes of pharmacological interventions, devices or implants on prospectively recruited human participants. Animal research, preclinical experiments, and optimization/validation of the intervention are not allowed.

***NOTE: The scope of research proposed in applications in response to the FY26 PRMRP program announcements must align with the research phases outlined above. It is the responsibility of the applicant to select the award mechanism that aligns with the scope of the proposed research. The funding mechanism should be selected based on the research scope defined in the program announcement, and not on the amount of the budget. Applications submitted under a mechanism that is not deemed appropriate for the scope of research proposed will not be funded.***

### 3.1. Award History

The PRMRP is offering the Platform Clinical Translation Award mechanism for the first time in FY26.

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### 3.2. Intent of the Platform Clinical Translation Award

The FY26 PRMRP Platform Clinical Translation Award (PCTA) supports the development of broadly applicable products or technologies that will address urgent and complex needs. Applications must address and provide a solution to **two of the congressionally directed FY26 PRMRP Topic Areas**. For the purposes of this funding opportunity, a platform is defined as a tangible or knowledge product base with the potential to improve the clinical care for multiple different medical conditions. Examples of platform products include broadly applicable treatments, multiplexed diagnostics, clinical decision-making technologies, gene-editing tools, stem-cell tools, and vaccine modalities. Proposed experiments should be milestone, rather than hypothesis, driven. Platform products in development should be responsive or have dual purpose potential for the health care needs of military Service Members, Veterans and their Families.

The FY26 PRMRP PCTA is designed to support the complexity and wide range of projects that are needed to advance a product that is truly applicable to multiple different diseases and/or conditions. The proposed experiments may represent a single project, led by a single PI, that will take a platform product through sequential milestone-driven phases of development. Alternatively, it may consist of multiple separate projects, led by a multidisciplinary team of individual project PIs, that will occur concurrently and synergistically to advance a platform product. In addition to the initiating PI, up to two partnering PIs may be identified. The proposed experiments should, at a minimum, cover all of the necessary milestones to complete preclinical development of the platform product. The study design may also include experiments and projects that extend past preclinical development and into initial, early-phase, clinical trials.

The PRMRP PCTA is not intended to support initial product discovery and is not intended to support products for research use only. Products should be supported by strong preliminary data demonstrating their readiness for clinical translation in the near future or as part of the proposed milestones. Preliminary data may include published data from the scientific literature and/or unpublished data from the laboratory of the PI or a member of the research team. For interventional products that will be regulated by the U.S. Food and Drug Administration (FDA), or equivalent, it is expected that the research outcome will be a regulatory filing or initial demonstration of safety in human participants. Applicants seeking funding for research products, products applicable to a single disease/condition, initial product discovery, or that will not be able to take their product all of the way through the final stages of preclinical development should consider one of the other FY26 PRMRP program announcements being offered. For information about these award mechanisms, see information contained in the [FY26 PRMRP Research Development Pipeline](#).

**The FY26 PRMRP PCTA mechanism supports translational research, [clinical research](#), and early phase 0 or phase 1 [clinical trials](#).** For help determining whether the proposed study meets the definition of a clinical research study or a clinical trial, refer to these [case study examples](#).

#### 3.2.1. FY26 PRMRP Topic Areas and Strategic Goals

To meet the intent of the funding opportunity, **all applications for FY26 PRMRP funding must specifically address the FY26 PRMRP topic areas as directed by the U.S. Congress and have direct relevance to military health.** Additionally, the PRMRP implements a portfolio-driven approach by grouping related topic areas with strategic goals as a framework within which to address critical gaps in major research areas. **All applications must address one of the FY26 PRMRP strategic goals as it relates to the portfolio-assigned FY26 PRMRP topic**

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

**area.** If the proposed research does not specifically address two FY26 PRMRP topic areas and one FY26 PRMRP strategic goal, then the government reserves the right to administratively withdraw the application. For this award mechanism, the applicant should select the FY26 PRMRP Portfolio that aligns to the primary congressionally directed FY26 PRMRP topic area and a corresponding continuum of care category and FY26 PRMRP strategic goal. The applicant should then select a secondary congressionally directed FY26 PRMRP topic area. The secondary topic area does not need to be, but can be, aligned to the same portfolio as the primary topic area. The continuum of care categories are listed as follows: foundational studies, epidemiology, prevention, diagnosis and treatment. The government reserves the right to reassign the application's topic area if submitted to an incorrect topic area. The section below lists the FY26 PRMRP topic areas and strategic goals in each PRMRP portfolio category.

### **FY26 PRMRP Portfolio Categories With Associated FY26 PRMRP Topic Areas and FY26 PRMRP Strategic Goals**

#### **AUTOIMMUNE DISORDERS AND IMMUNOLOGY**

***All applications under this portfolio must be aligned to Autoimmune Disorders and Immunology by addressing one topic area and one strategic goal listed below.***

#### **TOPIC AREAS**

- Celiac Disease
- Eczema
- Food Allergies
- Inflammatory Bowel Disease
- Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus (PANDAS)
- Sarcoidosis
- Scleroderma

#### **STRATEGIC GOALS BY CONTINUUM OF CARE**

##### **Foundational Studies**

- Investigate the mechanisms driving the pathobiology of the disease/condition.
- Investigate factors affecting disease/condition onset, progression, or heterogeneity, such as environmental exposures, comorbidities, behaviors, genetics, stress, infections, neuroimmune interactions, or microbiome dynamics.
- Investigate sex differences in the immune system.

##### **Epidemiology**

- Conduct patient-centered research to identify factors driving incidence trends, including recent increases.
- Conduct patient-centered studies to better understand differences between childhood- and adult-onset immune-mediated diseases/conditions, focusing on underlying pathobiology and treatment response.
- Conduct population-based studies to identify risk factors and enhance methods for detecting individuals at high risk.
- Conduct research to better understand sex differences in incidence and/or outcomes.
- Conduct population-based studies to examine variations in incidence and outcomes across different population subgroups.

##### **Prevention**

- Develop and test innovative strategies to prevent the onset, relapse, and/or progression of the disease/condition.
- Identify and test approaches to establish immune tolerance early in life.

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### Diagnosis

- Identify and validate biomarkers for continuous monitoring of disease/condition progression or to evaluate intervention response.
- Develop and validate improved diagnostic tools to enable early, accurate detection and to standardize diagnostic strategies.

### Treatment

- Develop and test curative and immune reset interventions.
- Develop and test therapies effective across all or multiple allergens or autoantigens.
- Develop and test strategies to improve outcomes, reduce inflammation, promote healing, provide neuroprotection, delay symptom onset, or minimize toxicity, including lifestyle changes, targeted drugs, nutraceuticals, and personalized treatments.
- Generate evidence for repurposing and off-label use of potential treatments.

## CARDIOVASCULAR HEALTH

***All applications under this portfolio must be aligned to Cardiovascular Health by addressing one topic area and one strategic goal listed below.***

### TOPIC AREAS

- Brain Injury Impact on Cardiac Health
- Hypoxia

### STRATEGIC GOALS BY CONTINUUM OF CARE

#### Foundational Studies

- Investigate the mechanisms driving the pathobiology of the disease/condition.
- Investigate the mechanisms driving cardiovascular dysfunction following brain injury.
- Enhance understanding of oxygen sensing and the biological response to low oxygen levels.
- Identify risk factors, with a focus on comorbidities and genetic predispositions.

#### Epidemiology

- Conduct population-based studies to monitor cardiovascular changes over time.
- Conduct population-based research to identify risk factors, including but not limited to brain injury, and improve methods to detect individuals at high risk.
- Conduct population-based studies to examine variations in incidence and outcomes across different population subgroups.

#### Prevention

- Develop and test strategies to prevent or reduce the impact of the disease/condition on the heart, brain, arteries, and additional target organs.
- Develop and test strategies to reduce/prevent risk factors associated with disease onset, progression, or complications.

#### Diagnosis

- Develop and test strategies to enhance detection accuracy and sensitivity, including strategies to identify maladaptive vascular remodeling or to enable continuous monitoring or detection of tissue- or cell-specific oxygen levels.
- Develop and validate less invasive diagnostic methods.
- Identify and validate biomarkers that reliably predict outcomes.

#### Treatment

- Generate evidence to support the repurposing and off-label use of treatments, including research on optimal dosing regimens.
- Develop and test innovative therapeutic strategies, with an emphasis on targeted, localized, and personalized approaches.

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### INFECTIOUS DISEASES

***All applications under this portfolio must be aligned to Infectious Diseases by addressing one topic area and one strategic goal listed below.***

#### TOPIC AREAS

- Congenital Cytomegalovirus
- Hepatitis B
- Tuberculosis

#### STRATEGIC GOALS BY CONTINUUM OF CARE

##### Foundational Studies

- Investigate the mechanisms of infection, transmission, pathogenicity, or drug resistance.
- Develop innovative preclinical models to investigate disease pathobiology, host response, and to support drug discovery and testing.
- Enhance understanding of interactions between infection and comorbid conditions.
- Identify risk factors contributing to adverse outcomes.
- Discover and evaluate new drug targets.

##### Epidemiology

- Conduct population-based studies to collect data on disease trends, including those establishing, affiliated with, or contributing to clinical networks, biorepositories, or databanks.
- Conduct population-based studies to improve understanding of transmission, disease progression, and risk factors for complications.
- Conduct retrospective studies to assess the impacts of disease on quality of life.

##### Prevention

- Develop and test strategies to prevent complications and adverse outcomes following infection.
- Develop and test innovative strategies to prevent disease onset or inhibit its progression.
- Develop and test methods to eliminate maternal-fetal transmission.

##### Diagnosis

- Develop and validate innovative diagnostic tools, focusing on less- or non-invasive methods, point-of-care applications, early detection, or improved sensitivity.
- Identify and validate biomarkers to improve infection diagnosis and/or prognosis, assess infection-related complications, or measure protection against infection.

##### Treatment

- Develop and test curative interventions or treatments that eliminate all symptoms, including precision medicine approaches and those that address latent infection.
- Develop and assess new therapeutic strategies that are more potent, act directly, require shorter dosing regimens, provide longer-lasting effects, better mitigate complications, address treatment resistance, and/or address latent infection.
- Generate evidence for optimal treatment regimens, including strategies tailored to specific age groups, combination therapies, and antiviral or vaccine dosing schedule recommendations.

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### INTERNAL MEDICINE

***All applications under this portfolio must be aligned to Internal Medicine by addressing one topic area and one strategic goal listed below.***

#### TOPIC AREAS

- Accelerated Aging Processes Associated with Military Service
- Endometriosis
- Hypertrophic Dyschromia
- Infertility Associated with Military Aviators and Aviation Support Personnel
- Interstitial Cystitis
- Pancreatitis
- Polycystic Kidney Disease

#### STRATEGIC GOALS BY CONTINUUM OF CARE

##### Foundational Studies

- Improve understanding of how military service or exposures contribute to physiological dysregulation, reproductive health issues, the aging process, and epigenetic changes.
- Investigate the mechanisms and pathophysiology underlying disease onset and/or progression.
- Improve understanding of disease/condition heterogeneity, comorbidities, systemic impacts, and long-term complications.

##### Epidemiology

- Conduct comparative studies to determine military-specific risks and enhance understanding of diseases/conditions that have increased incidence in the active-duty and Veteran population.
- Conduct population- and/or patient-based studies to improve understanding of disease heterogeneity and phenotypic variability.
- Conduct research to better understand sex differences in incidence and/or outcomes.
- Conduct population-, occupational-, and/or patient-based studies to identify risk factors that influence disease development, progression, treatment, and outcomes.

##### Prevention

- Develop and test strategies to reduce the health impacts of military service and exposures and prevent long-term consequences.
- Develop and test innovative strategies to prevent disease onset, progression, and/or associated comorbidities.

##### Diagnosis

- Develop and validate screening tools to detect conditions associated with premature aging processes.
- Develop and validate innovative diagnostic approaches, focusing on less invasive methods, faster timelines, and methods that account for disease heterogeneity.
- Develop and validate biomarkers, imaging techniques, or other tools for diagnosis, objective prognosis, subtype differentiation, monitoring, or assessing treatment response.
- Develop and validate methods for identifying and measuring toxic agents and their pathophysiological effects.

##### Treatment

- Develop and test efficacy of lifestyle and other non-drug interventions.
- Develop and test novel treatment strategies aimed at cures or improved symptom management to enhance quality of life, including drug repurposing studies, combination therapies, and innovative drug delivery techniques.
- Develop and assess strategies to enable personalized care recommendations or optimize treatments for specific population subgroups, including studies on the efficacy of existing treatment options.
- Develop and test innovative approaches for pain management as a symptom of the disease/condition.

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Develop and test innovative approaches to improve organ transplant outcomes or transplant alternatives, such as artificial organs, xenotransplants, and novel strategies to prevent rejection.

### NEUROSCIENCE AND MENTAL HEALTH

***All applications under this portfolio must be aligned to Neuroscience and Mental Health by addressing one topic area and one strategic goal listed below.***

#### TOPIC AREAS

- Brain Injury Impact on Cardiac Health
- Dystonia
- Eating Disorders
- Gambling Addiction
- Hydrocephalus
- Intranasal Ketamine Anesthetics
- Maternal Mental Health
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- PANS and PANDAS
- Peripheral Neuropathy
- Post-Traumatic Stress Disorder
- Sleep Disorders and Restrictions
- Suicide Prevention

#### STRATEGIC GOALS BY CONTINUUM OF CARE

##### Foundational Studies

- Investigate the mechanisms underlying disease/condition pathobiology, progression, and associated comorbidities at multi-organ/system, circuit, or cellular/molecular levels.
- Identify factors that predispose individuals to the disease/condition, predict adverse outcomes, or contribute to resilience.
- Enhance understanding of disease/condition heterogeneity, including variations in phenotypic, symptom, and behavioral presentation.
- Develop and evaluate innovative models that can be used to understand etiology and will facilitate drug discovery and testing.

##### Epidemiology

- Conduct population-based studies to identify and track trends and treatment responses, generating data on treatment efficacy to inform the development of personalized treatments.
- Conduct population-based studies to enhance understanding of risk factors and progression of disease/condition.
- Conduct comparative studies to identify military-specific aspects of diseases/conditions, including risk factors, comorbidities, quality of life impacts, treatment preferences, prevalence, and ability to return to duty.
- Conduct research to better understand sex differences in incidence and/or outcomes.
- Conduct population-based studies to examine variations in incidence and outcomes across different population subgroups.

##### Prevention

- Develop and test strategies to prevent the disease/condition, as well as its downstream complications, including methods for relapse prevention or mitigation of risk factors.
- Develop and test innovative strategies to maintain optimal cognitive functioning and mental resilience.

##### Diagnosis

- Develop and validate objective diagnostic methods that are accurate, sensitive, enable early detection, and account for heterogeneity in disease/condition phenotypes, includes screening tools.
- Identify and validate biomarkers that predict risk for the primary disease/condition and its secondary complications.
- Develop and validate methods for continuous monitoring and evaluating treatment efficacy.

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### Treatment

- Develop and test treatments to achieve curative or regenerative outcomes, preserve cognition, and enhance quality of life, including gene therapies, noninvasive stimulation techniques, alternatives to brain surgery, pharmaceuticals, and behavioral interventions.
- Evaluate repurposed drugs to accelerate strategies for improving symptom management and enhancing quality of life.
- Develop and assess guidelines for optimal intervention use, including evidence for safety and efficacy across diverse populations, precision medicine approaches, dosing regimens, safety monitoring, side effect management, and delivery methods.
- Develop and test innovative strategies to increase access to treatments, such as telemedicine approaches and adaptations tailored to specific populations.

## ORTHOPAEDIC MEDICINE

***All applications under this portfolio must be aligned to Orthopaedic Medicine by addressing one topic area and one strategic goal listed below.***

### TOPIC AREAS

- Accelerated Aging Processes Associated with Military Service
- Musculoskeletal Health
- Orthotics and Prosthetics Outcomes

### STRATEGIC GOALS BY CONTINUUM OF CARE

#### Foundational Studies

- Investigate mechanisms driving musculoskeletal disease/condition pathology and progression, focusing on muscle, connective tissue, genetics, epigenetics, aging, pain, sex differences, physical or mental stress, mechanobiology, cell senescence, and/or systemic interactions.
- Identify risk factors for orthopaedic diseases/conditions, including those that accelerate musculoskeletal degeneration, contribute to adverse outcomes, or lead to more severe symptoms.
- Develop and evaluate disease/injury using preclinical models to improve understanding of mechanisms and support intervention discovery and testing.
- Develop and evaluate small joint disease/injury models improve understanding of mechanisms and support intervention discovery and testing.
- Investigate the impact of life stage impacts musculoskeletal health and related diseases/conditions, including the effects of childhood growth, hormonal changes throughout the lifespan, and aging-related processes.

#### Epidemiology

- Leverage large data sets to generate evidence-based treatment guidelines to optimize joint longevity.
- Conduct patient-reported outcomes research incorporating both objective measures and quality-of-life metrics to evaluate treatment efficacy and guide intervention decisions.
- Conduct research to better understand sex differences in incidence and/or outcomes.
- Conduct comparative studies to better understand musculoskeletal degeneration in Veterans and identify military-specific risk factors.

#### Prevention

- Develop and test strategies that improve point-of-injury care, focusing on reducing the risk of secondary complications and promoting joint preservation.
- Optimize and test personalized treatment or rehabilitation plans to address adverse outcomes and mitigate risk factors.
- Develop and test strategies to prevent inflammatory joint damage caused by aging or overuse.

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### Diagnosis

- Develop and validate strategies for early and precise diagnosis of musculoskeletal dysfunction, including screening methods tailored for pediatric populations.
- Identify and validate biomarkers that indicate the severity or progression rate of musculoskeletal disease or age-associated degeneration.
- Identify and validate biomarkers or outcome measures to monitor disease/condition progression, understand variability, assess treatment efficacy, and evaluate impacts on quality of life.

### Treatment

- Advance innovative treatment strategies targeting etiology, preserving joint integrity, retaining functionality for daily activities, improving muscle strength and range of motion, reducing pain or fatigue, and/or regenerating damaged tissues.
- Develop and assess treatment strategies to enhance quality of life by increasing mobility, halting/slowing disease progression, or accelerating return to duty, including exercise regimens, regenerative or immune-modulating therapies, and device optimization.
- Develop and assess methods to optimize treatment, including patient-specific strategies, combination therapies, or refinement of intervention timing and dosing.
- Develop and test improved orthopedic devices, such as AI-driven auto-adjusting devices, better integrated designs for enhanced stability or accelerated healing, improved braces, prosthetic limbs, joint replacements, and strategies to enhance comfort.

## RARE DISEASES AND CONDITIONS

***All applications under this portfolio must be aligned to Rare Diseases and Conditions by addressing one topic area and one strategic goal listed below.***

### TOPIC AREAS

- |  |                             |
|--|-----------------------------|
| • Angelman Syndrome                          | • Hermansky-Pudlak Syndrome |
| • Ehlers-Danlos Syndrome                     | • Mitochondrial Disease     |
| • Facioscapulohumeral Muscular Dystrophy     | • Myotonic Dystrophy        |
| • Fibrous Dysplasia/McCune-Albright Syndrome | • Prader-Willi Syndrome     |
| • Fragile X                                  | • Rett Syndrome             |
| • Frontotemporal Degeneration                | • Sickle-Cell Disease       |
| • Hereditary and Acquired Ataxias            | • Spinal Muscular Atrophy   |
| • Hereditary Hemorrhagic Telangiectasia      | • von Hippel-Lindau Disease |

## STRATEGIC GOALS BY CONTINUUM OF CARE

### Foundational Studies

- Develop and evaluate innovative models for drug discovery and testing, with an emphasis on patient-derived cell models.
- Investigate the mechanisms driving symptoms to identify new strategies for symptom management, including novel drug targets and paradigm-shifting insights into pathobiology.

### Epidemiology

- Conduct population- or patient-based studies to evaluate intervention efficacy, incorporating patient-reported outcomes and objective metrics to refine clinical guidance, develop personalized treatments, and validate clinically relevant endpoints.
- Conduct population-based studies to monitor disease progression and identify factors that drive onset, progression, and outcomes.
- Conduct population-based studies to improve understanding of relationships between the disease/condition and comorbidities or conditions with shared symptoms.
- Integrate electronic medical records with real world data to improve the accuracy of prevalence estimates and guide precision medicine approaches.

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### Prevention

- Develop and test approaches to prevent complications associated with the disease/condition.
- Develop and test approaches, including gene therapy, to prevent symptoms or familial aggregation of the disease/condition.
- Develop and test evidence-based strategies to reduce disease/condition severity, including investigations promoting better health during pregnancy.

### Diagnosis

- Develop and validate diagnostic strategies that are objective, noninvasive, accurate, and enable early detection, subtype distinction, disease progression tracking, and complication prediction.
- Develop and validate methods to objectively measure symptoms and evaluate their impact on daily functioning.
- Develop and validate diagnostic, monitoring, or prognostic biomarkers.
- Identify and validate clinically relevant endpoints for assessing treatment response, suitable for use in FDA-regulated clinical trials.

### Treatment

- Develop and test innovative treatment approaches, emphasizing early intervention, therapies that slow/halt disease/condition progression, therapies that address phenotypic/subtype differences, and disease-modifying or curative treatments.
- Develop and assess strategies to optimize existing treatments to reduce side effects and tailor interventions to specific patients.
- Generate evidence to support and guide the use of off-label drugs for symptom relief.
- Develop and test pharmacological or non-pharmacological interventions to manage symptoms and improve quality of life for patients and caregivers, including strategies for care transitions.

## RESEARCH AND CLINICAL TOOLS

***All applications under this portfolio must be aligned to Research and Clinical Tools by addressing one topic area and one strategic goal listed below.***

### TOPIC AREAS

- Proteomics

### STRATEGIC GOALS BY CONTINUUM OF CARE

#### Foundational Studies

- Utilize proteomics to deepen understanding of the molecular mechanisms, progression, comorbidities, and long-term complications of the disease/condition/injury.
- Investigate the functional impact of post-translational modifications and proteoforms, beyond protein abundance, to guide management of the disease/condition/injury.
- Further the integration of proteomic databases and validated proteome subsets into advanced informatics tools.

#### Epidemiology

- Conduct population-based longitudinal proteomics studies to guide disease/condition/injury management strategies and support the development of personalized care approaches.
- Leverage existing proteomic databases to conduct large-scale research.

#### Prevention

- Develop and validate proteomics-based technologies to prevent the onset, progression, recurrence, and/or comorbidities of the disease/condition/injury.

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### Diagnosis

- Develop and validate proteomics-based technologies or biomarkers for early detection, accurate diagnosis, subtype differentiation, monitoring disease/condition progression, or evaluating treatment response.

### Treatment

- Develop and test proteomics-based technologies to support personalized treatment strategies.
- Use proteomics-based approaches to identify novel treatments or targets.

## RESPIRATORY AND ENVIRONMENTAL HEALTH

*All applications under this portfolio must be aligned to Respiratory and Environmental Health by addressing one topic area and one strategic goal listed below.*

### TOPIC AREAS

- Burn Pit Exposure
- Hypoxia
- Pulmonary Fibrosis
- Respiratory Health

### STRATEGIC GOALS BY CONTINUUM OF CARE

#### Foundational Studies

- Identify factors driving respiratory distress or chronic respiratory disease progression with the goal of identifying novel treatment targets.
- Investigate the mechanisms by which airborne hazards cause respiratory injury/disease, including research linking the toxicant to the specific pathobiology.

#### Epidemiology

- Conduct population-based studies to generate data on risk factors, disease progression, and treatment outcomes to guide personalized medicine approaches.
- Conduct retrospective studies to correlate toxicant exposure with long-term illnesses.

#### Prevention

- Develop and test strategies to prevent lung disease following exposure to airborne pollutants, toxicants, or infectious agents.
- Develop and test strategies to prevent the extent of lung damage caused by trauma, transfusion, mechanical ventilation, infection, acute respiratory distress syndrome, or hemorrhagic shock.

#### Diagnosis

- Identify and validate biomarkers to diagnose, monitor progression, and predict adverse outcomes and complications of chronic respiratory diseases.
- Identify and validate biomarkers to support the development of personalized treatment strategies.
- Develop and validate tools to enable early and accurate detection of respiratory diseases/conditions, focusing on noninvasive approaches and point-of-care strategies.
- Develop and test fieldable toolsets to monitor lung dysfunction.
- Develop and validate methods to quantify individual exposure levels to airborne hazards.

#### Treatment

- Develop and test innovative treatments to slow progression of the disease/condition and promote lung repair, emphasizing progress towards precision medicine and regenerative approaches.
- Develop and test treatments for respiratory infections.
- Develop and test minimally invasive or noninvasive methods of delivering oxygen and facilitating gas exchange when the lungs are compromised.
- Develop and test fieldable systems to treat lung injury in far-forward settings.

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### 3.2.2. Key Elements for the Platform Clinical Translation Award

- **Impact:** The PRMRP PCTA intends to support impactful research that will transform patient outcomes within the context of two congressionally directed [FY26 PRMRP Topic Areas](#). Proposed projects may include translational research, clinical research and early-phase clinical trials. Impactful research will accelerate the development of a platform product that will improve clinical care by delivering an improved treatment, diagnostic, or preventative strategy to the targeted patient population. The anticipated outcomes of the research should be expected to have a positive impact on the lives of the relevant patient population(s) in the short and/or long term.
- **Preliminary Data:** The FY26 PRMRP PCTA requires preliminary data appropriate to the proposed stage of development. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished and/or from the published literature. Unpublished data should originate from the laboratory of the PI or a member of the research team. For applications proposing preclinical translational platform product development experiments, proof of concept demonstrating the potential utility of the proposed platform product, or a prototype/preliminary version of the proposed product, should already be established. Applications supported by this award must begin with lead compounds in hand, or a device prototype, or an appropriate proof of concept for knowledge products; and must include preliminary data relevant to the phase of development. Examples of prototype and/or preliminary data include but are not limited to:
  - Proof of identity and purity
  - Selectivity for the intended target over closely related targets
  - Availability of primary and secondary in vitro bioactivity assays for optimization or structure-activity relationship studies
  - Availability of clear efficacy data in at least one relevant model system, with adequate power and methods
  - Demonstration of diagnostic or prognostic prediction in at least one relevant disease model
  - Demonstration of initial phases of prototype development and/or software development
  - Demonstration of access to data or tools needed to generate a knowledge product that will inform patient care

For applications proposing clinical trial testing of a platform product, the application must include preliminary data that is sufficient to demonstrate readiness of the proposed intervention, feasibility of completing the proposed trial, and feasibility of generating interpretable data. If generation of the data to demonstrate readiness of the intervention is part of the proposed experiments, there must be clear milestones specifying the data to be gathered and the interpretation of the data that will be needed for the trial to move forward.

- **Product Development and Testing:** The program expects award recipients to submit an Investigational New Drug/Investigational Device Exemption (IND/IDE) application to the FDA, to demonstrate initial safety in a healthy human population, or to transition the product to clinical practice or to the intended end user, by the end of the period of performance. Examples of the types of activity expected for this stage of product development to be part of the proposed research plan include, but are not limited to:

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Confirming efficacy and/or safety of therapeutic modalities (agents, delivery systems, and chemical modification of lead compounds) using established or validated preclinical systems
- Implementing full-scale Good Manufacturing Practice (GMP) production of therapeutics and/or delivery systems for use in advanced preclinical and initial clinical trials
- Validating pharmacologic agents through absorption, distribution, metabolism, excretion, and toxicity studies
- Developing pharmacologic agents to IND stage for initiation of phase 1 clinical trials
- Developing prototype devices to IDE stage or abbreviated IDE stage for initiation of clinical trials
- Optimizing diagnostic or treatment devices for field deployment
- Developing clinical decision making tools to the clinical testing stage
- Conducting clinical research to validate a diagnostic strategy
- Finalizing and submitting a regulatory submission for phase 0/1 clinical trials
- Conducting phase 0/1 clinical trials to demonstrate safety, dosing and pharmacokinetics
- Conducting non-phased trials to demonstrate initial clinical efficacy of a knowledge product or clinical decision making tool
- **Study Design:** Applications should clearly articulate the chosen design of the study and describe all projects and aims with sufficient detail to explain the data that will be generated, how that data will be analyzed, the milestones that will be met, and how the results will be interpreted to inform further product development and translation. Studies entailing multiple projects and/or multidisciplinary teams must clearly articulate the synergy and how it will be maintained throughout the period of performance. Applications proposing interdependent projects that are contingent upon the success of one another must have clearly articulated the milestones that will need to be met before the sequential experiments are initiated. These types of sequential efforts should be separated within the budget. The government reserves the right to fund sequential projects as optional research phases.
- **Implementation:** The research strategy must be supported by a detailed implementation plan that identifies critical milestones and outlines the knowledge, resources, and technical innovations that will be utilized to achieve the milestones. A robust statistical plan and statistical expertise should be included where applicable. Plans to include an advisory board are required. For multi-institutional collaborations, plans for communication and data transfer among the collaborating institutions, as well as how data, specimens, and/or products obtained during the study will be handled, must be included. An intellectual and material property plan agreed to by participating organizations is required in the application's supporting documentation.
- **Advisory Board:** The research team is expected to form and convene an advisory board to provide mentorship and advising for the PCTA throughout the award progress. The advisory board must include the PI, site PIs/ collaborators and at least one patient advocate.
  - **Patient Advocate:** The patient advocate will be a person living with, or a family member or caretaker of someone with, a disease or condition addressed in one of the congressionally directed [FY26 PRMRP Topic Areas](#). As a lay representative, the patient advocate should be active in an advocacy organization. The patient advocate should be

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

involved in the development of the research question, project design, oversight, and evaluation, as well as other significant aspects of the proposed project. Interactions with other team members should be well-integrated and ongoing, not limited to attending seminars and semi-annual meetings. The role of the patient advocate should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, a disease or condition addressed in two of the congressionally directed [FY26 PRMRP Topic Areas](#).

- **Partnering PI Option:** The PCTA includes an option for more than one PI. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. Up to two additional PIs can be identified as Partnering PIs. All PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to [Section 5.3, Submission Instructions](#).
- **Milestone Meeting:** The government reserves the right to require the PI to present an update on progress toward accomplishing the goals of the award at a Milestone Meeting. The Milestone Meeting will be held virtually and be timed to make decisions on whether milestones have been met and whether data is sufficient to move forward with optional or sequential research phases. The PI may bring up to three additional members of the research team to the meeting. The Milestone Meeting will be attended by members of the PRMRP Programmatic Panel, CDMRP Staff, the DHACA Grants Officer, and other DOW stakeholders.
- **Relevance to Military Health:** The program expects awards to address relevance to the health care needs of military Service Members, Veterans and their Families. The PRMRP encourages applicants to consider the following characteristics as examples of how a project may demonstrate relevance to military health:
  - Explanation of how the project addresses an aspect of the target disease/condition/technology that has direct relevance to the health of military Service Members, Veterans and their Families.
  - Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to benefit the civilian population and also address a military need.
  - Use of military or Veteran populations, samples, or datasets in the proposed research, if appropriate.
  - PIs are encouraged to integrate and/or align their research projects with DOW and/or VA research laboratories and programs. Collaboration with the DOW and/or VA is also encouraged. A list of websites that may be useful in identifying additional information about ongoing DOW and VA areas of research interest or potential opportunities for collaboration can be found in [Appendix 10](#) of the GAI.

### 3.2.3. Other Important Considerations for the Platform Clinical Translation Award

The FY26 PRMRP PCTA supports a combination of translational research, clinical research, and clinical trial activities to advance the platform product through the final stages of translational development and into early-phase trials. This award is designed to fund projects and objectives that may be interdependent and sequential. Later-stage projects and objectives,

## Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)  
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

which rely on the successful completion of earlier milestones, will be funded as optional research phases. The agreement to support optional efforts will be contingent upon (1) accomplishment of research milestones and goals as determined by the PRMRP Programmatic Panel and DHACA Grants Officer; and (2) the availability of funds.

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the [STROBE](#), [CONSORT](#), [SPIRIT](#) and [ARRIVE 2.0](#) guidelines.

### 3.3. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

### 3.4. Funding Details

**Period of Performance**: The maximum period of performance is **4** years.

**Cost Cap**: The application's total costs budgeted for the entire period of performance should not exceed **\$15M, of which only \$8M is currently available**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **4** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

The applicant may request up to \$8M in total costs for the base award. This will be funded using allocation from the FY26 PRMRP Congressional appropriation. The research activities conducted under the base award should be all activities planned to start within the first year of the period of performance. These research activities should not be contingent upon successful completion of other major project milestones.

In addition, the applicant may request an option period of up to \$7M in total cost to fund additional research activities. This option period should be planned to be conducted within the maximum period of performance (up to 4 years) and include any activities that are contingent upon the successful completion of earlier project milestones. For example, if the proposed research includes preclinical development of an intervention and a clinical trial testing that intervention, the trial portion should be separated into the option period to be conducted only after the preclinical development has been successfully completed. Funding for this option period is contingent upon receipt of future Congressional appropriations. ***Budgets for this option period should be submitted using the Research & Related Subaward Budget Attachment(s) Forms.***

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

The government reserves the right to adjust the immediately available base award budget level to separate sequential experiments into optional research phases.

**Application submissions with the Partnering PI Option:** The combined total costs budgeted for the entire period of performance in the applications of the Initiating PI and each Partnering PI should not exceed **\$15M, of which only \$8M is currently available**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

- A separate award will be made to each PI's organization.
- If requesting funds above the currently available \$8M, the initial \$8M of the budget should be accounted for separately, with any additional work described as optional and budgeted independently. Additional funding for this optional work may be dependent on the availability of future year funds. ***Budgets beyond \$8M should be submitted using the Research & Related Subaward Budget Attachment(s) Forms.***

**Direct Cost Restrictions:** For this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Travel in support of multi-institutional collaborations.
- Costs for three investigators to travel to one scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the FY26 PRMRP Platform Clinical Translation Award.
- Research participant compensation and reimbursement for trial-related out-of-pocket costs (e.g., travel, lodging, parking, costs associated with caregiving, and resources/equipment to enable participation).

Must not be requested for:

- Costs for travel to scientific/technical meeting(s) beyond the limits stated above.
- Tuition.

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

# 4. Application Contents and Format

## 4.1. Application Overview

Application submission is a two-step process requiring both a **pre-application** submitted via the Electronic Biomedical Research Application Portal ([eBRAP](#)) and a **full application** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

***Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.***



***Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.***



## 4.2. Pre-Application Components

The PI or Initiating PI must submit the following pre-application components.

Include the FY26 PRMRP portfolio, two congressionally directed [FY26 PRMRP Topic Areas](#), FY26 PRMRP continuum of care category, and [FY26 PRMRP Strategic Goal](#) under which the application will be submitted.

Select the appropriate mechanism option as described in [Section 5.3.1. Pre-Application Submission](#).

***Upload documents as individual PDF files unless otherwise noted. Files must comply with the [formatting guidelines](#) listed in the GAI.***

- **Preproposal Narrative (six-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.


The Preproposal Narrative should include the following:

- **Platform Product Description:** Describe the broadly applicable product or technology that will be developed and or tested and how it will have impact for two congressionally directed [FY26 PRMRP Topic Areas](#). Clearly articulate the current stage of development for the proposed product and the intended use of the product.
- **Research Strategy:** Proposed research must be milestone-driven. State the project(s) to be conducted, the hypothesis(ses) to be tested or the final development milestone to be met, the specific aims, and the objectives to be reached. Briefly describe the experimental approach.
- **Clinical Trial (if applicable):** If the proposed research project includes a clinical trial, briefly state the clinical intervention(s), participant population(s), and the type and phase of the clinical trial(s). Describe the objectives of the clinical trial(s) and the primary outcome(s).
- **Impact:** Describe the potential short-term impact of the proposed research on a critical problem or question in the field of research and/or patient care aligned to the two congressionally directed [FY26 PRMRP Topic Areas](#) addressed. Describe how the

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

research will fulfill one of the [FY26 PRMRP Strategic Goals](#). Explain how the effort is relevant to the health care needs of military Service Members, Veterans and/or beneficiaries.

- **Personnel:** Briefly describe the composition, expertise, and organization of the PI and key personnel. Note any DOW- or VA-relevant collaborations.
- **Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application **must be uploaded as individual files** and are limited to the following:
  - **References Cited (one-page limit):** List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers, and publisher, as appropriate).
  - **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative.
  - **Key Personnel Biographical Sketches:** **All biographical sketches should be uploaded as a single combined file.** Biographical sketches should be used to demonstrate background and expertise through education, positions, publications, and previous work accomplished. 

### 4.3. Full Application Components

Applicants must receive an invitation to submit a full application. Uninvited full application submissions will be rejected.

**Partnering PI Option:** The CDMRP requires separate full application package submissions for the Initiating PI and each Partnering PI, even if the PIs are located within the same organization. The application submission process for each Partnering PI uses an [abbreviated full application package](#).

#### 4.3.1. Full Application Components for the PI or Initiating PI

Each application submission must include the completed full application package for this program announcement. See [Appendix 1](#) for a checklist of the full application components.

- (a) **SF424 Research & Related Application for Federal Assistance Form (*Grants.gov submissions only*):** 

***IMPORTANT:*** When completing the SF424 R&R, enter the **eBRAP log number** assigned during pre-application submission into **Block 4a – Federal Identifier**.

- (b) **Attachments:**

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the [formatting guidelines](#) in the GAI.

- **Attachment 1: Project Narrative (40-page limit): Upload as “ProjectNarrative.pdf”.** 

Describe the proposed project in detail using the outline below.

- **Background:** Describe the platform product to be developed and how it is relevant to two congressionally directed [FY26 PRMRP Topic Areas](#). Additionally, describe how the proposed product addresses a critical problem or question in the field of

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

research and/or patient care in the [FY26 PRMRP Topic Areas](#) addressed. Clearly articulate the rationale for the study design. **Include relevant literature citations and preliminary data and/or promising preclinical findings that demonstrate proof of concept for the product or a prototype/preliminary version of the product. Preliminary data should be appropriate for the proposed stage of development and include the following as appropriate: proof of identity and purity; demonstrate selectivity; demonstrate diagnostic or prognostic prediction in at least one relevant disease model; demonstrate existence of a prototype; demonstrate access to data or tools that will be required; demonstrate availability and/or feasibility of assays; show efficacy in an appropriate model system, etc.** The data may be unpublished or from published literature. Unpublished preliminary data should originate from the laboratory of the PI or a member of the study team.

If a clinical trial is proposed, include a discussion of any current clinical use of the intervention under investigation, and/or details of its study in clinical trials for other indications (as applicable). Describe how the study would be expected to make an impact on the lives of relevant patient populations in the short term and or long term. If the proposed clinical trial was initiated using other funding prior to this application, explain the history and background of the clinical trial and declare the source of prior funding. Specifically identify the portions of the study that will be supported with funds from this award.

- **Objectives, Specific Aims and Hypotheses:** State the hypothesis to be tested and/or the objective(s) to be reached. Describe how the proposed research project(s) addresses one of the [FY26 PRMRP Strategic Goals](#). Provide a detailed description of the specific aims and/or study questions. If a clinical trial is proposed, clearly define the type of trial to be conducted, the phase of the clinical trial, and the primary projected outcome(s) of the clinical trial.
- **Research Strategy and Feasibility:** Describe the study design, methods, and analyses in sufficient detail for evaluation including availability of resources (if applicable). Provide a well-developed, well-integrated research strategy that supports the translational feasibility and promise of the approach. Define the specific study outcomes and how they will be measured. Address potential problem areas and present alternative methods and approaches. Describe how data will be collected and handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, and identification of primary endpoints/outcomes. Consult appropriate [guidelines](#) to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported. Describe interactions with regulatory agencies as appropriate for the product under development.

Describe the statistical methodology and analysis plan including how it supports the stated hypothesis or objective. Include a description of the power analysis and whether it determined experimental population numbers; if not, justify why the power analysis is not essential to the statistical evaluation. Additionally, state whether the study will include univariate, bivariate, or multivariate analyses. State the variables to be used in the main analysis; include covariates and how the data will be adjusted to account for covariates, if applicable. Stratification of data (if applicable) should be described and justified

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

If animal studies are proposed, briefly describe the key elements of the study/studies as they relate to the overall project. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and, where appropriate, the study's relevance to human biology. Describe the randomization and blinding procedures for the study and any other measures to be taken to minimize effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.

For studies entailing [clinical research](#) (e.g., descriptive, correlational, field experimental, meta-analyses), study populations should be defined. Address potential problem areas and potential pitfalls, and present alternative methods and approaches. If using psychometric measures, describe their reliability and validity. If use of a biorepository, patient medical files, or meta-analysis is proposed, describe the data to be collected and the process or methodology to collect the samples (i.e., for biorepositories – the standardization of procedures for collection). If human participants or human anatomical samples will be used, include a plan for the recruitment of participants or the acquisition of samples and document the experience of the PI and/or key collaborators in recruiting human participants for similar projects. If the proposed research will use existing datasets (e.g., clinical databases, genomic databases, or other datasets), describe the dataset(s) including the data source, sample size, variables available, quality control procedures, and evidence of access.

- **Implementation Plan and Environment:** Provide an overall strategic implementation plan for completing the proposed projects that identifies critical milestones and explain how these milestones will be achieved. Outline the knowledge, expertise, and technical innovations that the investigative team will utilize to make decisions, allocate resources, and accomplish the milestones. Describe and/or provide evidence that the research can be initiated without delay once the award is made. Present an overall management plan to facilitate a consistent and intensive flow of ideas and information among all team members, including aspects such as adherence to regulatory requirements, administrative support, and oversight to accelerate translation of the projects' outcomes to patients and/or for clinical use. Describe the research environment and how the facilities and resources will support the research requirements and the collaboration. Outline shared resources and/or cores that will be created and/or leveraged through the award. Describe plans for communication, data transfer among the collaborating institutions, and how data, specimens, and/or imaging products obtained during the study will be handled. If applicable, describe how Standard Operating Procedures will be created, reviewed, implemented, and modified during the course of the award.
- **Advisory Board:** Describe the role of the advisory board and the expertise to be sought in its members. The advisory board must include the PI, site PIs/collaborators, and at least one patient advocate. Describe the interactions and integration between the advisory board and the project team members.
  - **Patient Advocate:** Describe the involvement of the patient advocate in the development of the research question, project design, oversight, and evaluation of the projects. Explain how the patient advocate provides input on the project and its potential impact for individuals with, or at risk for, a disease or condition addressed in two or more of the congressionally directed [FY26 PRMRP Topic Areas](#).

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Statistical Plan and Data Analysis:** Describe the statistical model and data analysis plan with respect to the study objectives. If applicable, specify the approximate number of human participants to be enrolled. If multiple study sites are involved, state the approximate number to be enrolled at each site. Include a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study and all proposed correlative studies. If a subpopulation of a recruited sample population will be used for analysis, complete a statistical analysis to ensure appropriate power can be achieved within the subpopulation study. Ensure sufficient information is provided to allow thorough evaluation of all statistical calculations during review of the application.

Consult appropriate [guidelines](#) to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported.

- **Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”.**



***There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.***

- **References Cited:** List the references cited in the Project Narrative using a standard reference format (include URLs, if available).
- **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols.
- **Facilities, Existing Equipment and Other Resources:** Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.
- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
- **Letters of Support:** Provide individual letters as follows:
  - Letters of Collaboration (if applicable): Provide letters from collaborating individuals/organizations.
  - Letter of Eligibility Confirmation (required): Provide a letter from the Department Chair or equivalent confirming PI meets [eligibility criteria](#) and has necessary resources.
  - Letter from Patient Advocate (required): Provide a letter from the patient advocate confirming their participation as a member of the advisory board.
  - Letters of Access (if applicable): Provide a letter from the lowest-ranking person with approval authority confirming participation of intramural DOW collaborator(s), access to access to military populations, databases or DOW resources. Additionally, provide a letter indicating access to VA military

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

populations, databases or resources, provide a letter signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.

- **Intellectual and Material Property Plan (if applicable):** Provide a plan for resolving intellectual and material property issues among participating organizations.
- **Inclusion Enrollment Report (only required if [clinical research](#) and/or a [clinical trial is proposed](#)):** Provide an anticipated enrollment table(s) for the inclusion of women and minorities using the "[Public Health Service \(PHS\) Inclusion Enrollment Report](#)", a three-page fillable PDF form, that can be downloaded from eBRAP. The enrollment table(s) should be appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex, race, and ethnicity. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from IRB review) are exempt from this requirement.
- **Sex as a Biological Variable Strategy (two-page limit):** Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the [CDMRP Directive on Sex as a Biological Variable in Research](#) for additional information.
- **Research Sharing Plan:** Describe the type of data or research resources (e.g., bio-specimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g. for intellectual property, feasibility, cost, or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

***Do not submit a copy of the National Institutes of Health Data Management and Sharing Plan or duplicate the Data Management Plan which will be requested only after a recommendation for funding is made.***

Refer to the [CDMRP Directive on Sharing Data and Research Resources](#) for more information about the CDMRP's expectations for making data and research resources publicly available.

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Use of DOW Resources or VA Resources (if applicable):** If the proposed research involves access to military and/or VA patient populations and/or DOW or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Also include a plan for obtaining any required data sharing, memorandum of understanding or other agreements required to access and publish data. Refer to the GAI, [Appendix 4](#), for additional considerations.

- **Attachment 3: Technical Abstract (three-page limit): Upload as “TechAbs.pdf”.** 

Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

- **Background:** Present the scientific rationale behind the proposed research project.
- **Relevance to Topic Areas:** State the two congressionally directed [FY26 PRMRP Topic Areas](#) and [FY26 PRMRP Strategic Goal](#) that will be addressed by the project. The topic area and strategic goal should be phrased exactly as they appear in section 3.2.1 and paraphrasing should be avoided. Additionally, describe how the proposed research project will address the two stated congressionally directed [FY26 PRMRP Topic Areas](#) and [FY26 PRMRP Strategic Goal](#).
- **Hypothesis/Objective(s):** Define the project(s) and state the hypothesis(es) to be tested and/or objective(s) to be reached for each project.
- **Specific Aims:** State the specific aims of the study. If there will be multiple projects, state the aims/objectives for each individual project. If a clinical trial is proposed, include a description of the type of trial to be conducted, the phase of trial (if applicable), and the primary projected outcome(s) of the trial.
- **Study Design:** Describe the study design, including appropriate controls.
- **Impact:** Briefly describe how the proposed project will have a near-term impact on research and patient care in the specified disease(s)/condition(s).
- **Military Relevance:** Describe how the study is relevant to military health.


- **Attachment 4: Lay Abstract (three-page limit): Upload as “LayAbs.pdf”.** 

The lay abstract should address the points outlined below *in a manner that is readily understood by readers without a background in science or medicine*. Avoid overuse of scientific jargon, acronyms and abbreviations. **Do not duplicate the technical abstract.**

- State the two congressionally directed [FY26 PRMRP Topic Areas](#) and [FY26 PRMRP Strategic Goal](#) that will be addressed by the project. The topic area and strategic goal should be phrased exactly as they appear in section 3.2.1 and paraphrasing should be avoided. Additionally, describe how the proposed research project will address the two stated congressionally directed [FY26 PRMRP Topic Areas](#) and [FY26 PRMRP Strategic Goal](#).
- Summarize the objectives and rationale for the proposed research.
- What population will the research help, and how will it help them?
- What are the potential applications, benefits, and risks of the anticipated outcomes?

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- What are the likely contributions of the proposed research project to advancing research, patient care and/or quality of life?
- What is the potential benefit of the proposed study and the anticipated outcomes to Service Members, Veterans and their Families?
- **Attachment 5: Statement of Work (five-page limit): Upload as “SOW.pdf”.**  Refer to eBRAP for the [Suggested SOW Format](#).  
  
For guidance on preparing the SOW, refer to either the [Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work](#) or [Example: Assembling a Generic Statement of Work](#), whichever is most appropriate for the proposed effort. Include milestones for data or research resource(s) sharing.  
  
***Each PI must submit an identical copy of a jointly created SOW. The specific contributions of the Initiating PI and each Partnering PI should be clearly noted for each task.***
- **Attachment 6: Impact Statement (three-page limit): Upload as “Impact.pdf”.** The impact statement summarizes the potential short-and long-term impact of the proposed research. **The statement should address the points outlined below written in a manner that is readily understood by readers without a background in science or medicine.**
  - Explain how the proposed research project will address a critical problem or question in two of the congressionally directed [FY26 PRMRP Topic Areas](#). Additionally, describe how the project addresses one of the [FY26 PRMRP Strategic Goals](#).
  - Describe how the proposed research project, if successful, will make important scientific advances in the relevant field of research, and advance patient care for the target populations in the near term.
  - **Describe the short-term impact:** Detail the anticipated outcome(s)/product(s) (knowledge and/or materiel) that will be directly attributes to the results of the proposed research. Describe how the results of the research will improve patient care in the near term as compared to current practice or currently used treatments. Explain the evidence-based burden of disease for the conditions that are applicable to the platform product and how the proposed research will lessen the burden.
  - **Describe the long-term impact:** Explain the long-range vision for implementation of the product in the clinic or field, and describe the anticipated long-term benefits for the targeted populations, including impacts on patient care and/or quality of life.
    - Describe any potential issues that might limit the impact of the proposed study.
    - If a clinical trial is proposed, describe how the intervention compares with, or will complement, currently available interventions and/or standards of care for the applicable diseases/conditions.
- **Attachment 7: Relevance to Military Health Statement (one-page limit): Upload as “MilRel.pdf”.** **Attachment 7 will be available for programmatic review only.**
  - Describe how the proposed study is responsive to the health care needs of military Service Members, Veterans and their Families. Provide information about the incidence and/or prevalence of the disease or condition in the general population as well as in military Service Members, Veterans and their Families.

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- If active-duty military, military Families, and/or Veteran population(s) or datasets will be used in the proposed research project, describe the population(s)/dataset(s) and the appropriateness of the population(s)/dataset(s) for the proposed study. If a non-military population will be used for the proposed research project, explain how the population simulates the targeted population (i.e., military Service Members, Veterans and their Families).
- If applicable, show how the proposed research project aligns with DOW and/or VA areas of research interests. Provide a description of how the knowledge, information, products, or technologies gained from the research could be implemented in a dual-use capacity to benefit the civilian population and address a military need, as appropriate.
- **Attachment 8: Clinical Strategy and Recruitment Statements, if applicable (no page limit): Upload as “Clinical.pdf”. (*Attachment 8 is only applicable and required for applications proposing clinical trials*).**

### Clinical Strategy:

- Describe the rationale for the proposed clinical trial. Provide a description of the intervention and the endpoints to be measured. Describe the type of clinical trial to be performed (e.g., prospective, randomized, controlled) and outline the proposed methodology in sufficient detail to show a clear course of action. Describe potential challenges and alternative strategies where appropriate.
- If the proposed clinical trial was initiated using other funding prior to this application, explain the history and background of the clinical trial and declare the source of prior funding. Specifically, identify the portions of the study that would be supported with funds from this award.
- Provide detailed plans for initiating the clinical study within the first year, including FDA IND/IDE application submission plans within 60 days of the award, if applicable. Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the FDA, if applicable.
- Indicate the access to the study population, recruitment plans, and inclusion/exclusion criteria. Describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, racial, and ethnic group, and an accompanying rationale for the selection of participants. Provide an anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race, and ethnicity using the [Public Health Service \(PHS\) Inclusion Enrollment Report](#), which is a three-page fillable PDF form, that can be downloaded from eBRAP.
- **Regulatory Considerations (if applicable):** For investigator-sponsored regulatory exemptions (e.g., IND, IDE) provide evidence of institutional support. Provide evidence that the clinical trial does not require an IND/IDE. If the clinical trial will be conducted at international sites, provide equivalent information relevant to the regulatory requirements of the host country(ies).

### Study Population and Recruitment and Safety Plan:

- **Study Population:** Describe the target population (to whom the study findings will be generalized) and the nature, approximate number, and pertinent demographic characteristics of the accessible population at the study site(s) (population from

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- whom the sample will be recruited/drawn). Provide a table of anticipated enrollment counts at each study site. **Demonstrate that the research team has access to the proposed study population at each site, and describe the efforts that will be made to achieve accrual goals.** Provide justification related to the scientific goals of the proposed study for limiting inclusion of any group by age, race, ethnicity, or sex. **For clinical trials proposing inclusion of military populations, refer to the GAI, [Appendix 4](#), for more information.**
- **Inclusion/Exclusion Criteria:** List the inclusion and exclusion criteria for the proposed clinical trial. Provide detailed justification for exclusions.
  - **Description of the Recruitment Process:** Explain methods for identification of potential human participants (e.g., medical record review, obtaining sampling lists, health care provider identification). Describe the recruitment process in detail. Address who will identify potential human participants, who will recruit them, and what methods will be used to recruit them. Address the availability of human participants for the clinical trial for each enrollment site. If human participants will be compensated for participation in the study, include a detailed description of and justification for the compensation plan. Describe the recruitment and advertisement materials. Discuss past efforts in recruiting human participants from the target population for previous clinical trials (*if applicable*). Address any potential barriers to accrual and plans for addressing unanticipated delays, including a mitigation plan for slow or low enrollment or poor retention. Identify ongoing clinical trials that may compete for the same patient population and how they may impact enrollment progress.
  - **Women and Minorities Recruitment/Retention Strategy:** Describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, racial, and ethnic group, and an accompanying rationale for the selection of participants. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from IRB review) are exempt from this requirement. Anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race, and ethnicity should be provided as part of the application's Supporting Documentation ([Attachment 2](#)). Refer to the [CDMRP Directive on Inclusion of Women and Minorities as Subjects in Clinical Research](#) for additional information.
  - **Description of the Informed Consent Process:** Specifically describe the plan for obtaining informed consent from human participants.
    - **For the proposed study, provide a draft, in English, of the Informed Consent Form.**
    - Identify who is responsible for explaining the study, answering questions, and obtaining informed consent. Include a plan for ensuring that human participants' questions will be addressed during the consent process and throughout the trial.
    - Include information regarding the timing and location of the consent process.
    - Address issues relevant to the mental capacity of the potential human participant (e.g., altered capacity due to administration of any mind-altering substances such as tranquilizers, conscious sedation or anesthesia, brain injury, stress/life situations, or human participant age), if applicable.

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Address how privacy and time for decision-making will be provided and whether the potential human participant will be allowed to discuss the study with anyone before making a decision.
  - Consider the need for obtaining ongoing consent or for re-assessing capacity over the course of a long-term study, and describe any relevant procedures to assure continued consent.
  - Describe the plan for the consent of the individual's Legally Authorized Representative (LAR) to be obtained prior to the human's participation in the study. State law defines who may act as the LAR. The local IRB of record should be consulted for guidance regarding who can serve as LAR for research at the study site. **Note:** In compliance with 10 USC 980, the application must describe a clear intent to benefit human participants who cannot give their own consent to participate in the proposed clinical trial.
  - **Assent:** If minors or other populations that cannot provide informed consent are included in the proposed clinical trial, a plan to obtain assent (agreement) from those with capacity to provide it, or a justification for a waiver of assent, should be provided. PIs should consult with their local IRB to identify the conditions necessary for obtaining assent.
- **Screening Procedures:** List and describe any evaluations (e.g., laboratory procedures, history, or physical examination) that are required to determine eligibility/suitability for study participation and the diagnostic criteria for entry.
  - **Risks/Benefits Assessment:**
    - **Foreseeable risks:** Clearly identify all study risks, including potential safety concerns and adverse events. If applicable, any potential risk to the study personnel should be identified.
    - **Risk management and emergency response:** Appropriate to the study's level of risk, describe how safety monitoring and reporting to the IRB and Regulatory Agency (if applicable) will be managed and conducted. Describe all safety measures to minimize and/or eliminate risks to human participants and study personnel or to manage unpreventable risks. Include safeguards and planned responses, such as dose reduction or stopping criteria based on toxicity grading scales or other predetermined alert values. Discuss the overall plan for provision of emergency care or treatment for an adverse event for study-related injuries, including who will be responsible for the cost of such care.
    - **Potential benefits:** Describe known and potential benefits of the study to the human participants who will participate in the study. Articulate the importance of the knowledge to be gained as a result of the proposed research. Discuss why the potential risks to human participants are reasonable in relation to the anticipated benefits to the human participants and others that may be expected to result.
  - **Attachment 9: Animal Research Plan (three-page limit): Upload as "AnimalResPlan.pdf". (Attachment 9 is only applicable and required for applications proposing animal studies.)**

If the proposed study involves animals, a summary describing the animal research that will be conducted must be included in the application. Consult the [ARRIVE guidelines 2.0](#) (Animal Research: Reporting *In Vivo* Experiments) to ensure relevant aspects of

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information



rigorous animal research are adequately planned for and, ultimately, reported. The Animal Research Plan may not be an exact replica of the protocol(s) submitted to the Institutional Animal Care and Use Committee (IACUC). The Animal Research Plan should address the following points to achieve reproducible and rigorous results for each proposed animal study:

- Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and, where appropriate, the study’s relevance to human biology.
  - Summarize the procedures to be conducted. Describe how the study will be controlled.
  - Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.
  - Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.
  - Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis, and identification of the primary endpoint(s).
- **Attachment 10: Partnership Statement (one-page limit): Upload as “Partnership.pdf”. (*Attachment 10 is only applicable and required for applications with the Partnering PI Option.*)**
    - Describe the expertise of the Initiating and Partnering PIs and how each will bring different strengths to the proposed project. Describe how the combined clinical background and experience of the partnering investigators and other key personnel will enhance the application’s impact on patient outcomes.
    - Describe how the PIs’ unique expertise combined as a partnership will better address the research question; how the unique expertise that each PI brings to the project is critical for the research strategy and completion of the SOW; and why the work should be done together rather than through separate efforts.
    - Outline the contribution and time commitment of each partner and how each will have equal intellectual input on the design, conduct, and analysis of the project.
    - Describe how the PIs will manage the collaboration and workflow to optimize research efforts.
  - **Attachment 11: Post-Award Transition Plan (three-page limit): Upload as “Transition.pdf”.**

Describe/discuss the methods and strategies proposed to move the research products to the next phase of development (FDA-required IND-/IDE-enabling studies, clinical trials, commercialization, and/or delivery to the civilian or military market) after successful completion of the award. Applicants are encouraged to work with their organization’s Technology Transfer Office (or equivalent) to develop the transition plan. PIs are encouraged to explore developing relationships with industry and/or other funding agencies to facilitate moving the product into the next phase of development. The post-award transition plan should include the components listed below:

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Details of the funding strategy to transition to the next level of development and/or commercialization (e.g., specific industry partners, specific funding opportunities to be applied for). Include a description of collaborations and other resources that will be used to provide continuity of development.
  - For knowledge products, a description of collaborations and other resources that will be used to provide continuity of development, including proposed development or modification of clinical practice guidelines and recommendations, provider training materials, patient brochures, and other clinical support tools, scientific journal publications, models, simulations, and applications. (A “knowledge product” is a non-materiel product that addresses an identified need, topic area, or capability gap; is based on current evidence and research; aims to transition into medical practice, training, or tools or to support materiel solutions [systems to develop, acquire, provide, and sustain medical solutions and capabilities]; and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.)
  - A brief schedule and milestones for transitioning the intervention to the next level of development (e.g., FDA-required IND-/IDE-enabling studies, next-phase clinical trials, commercialization, delivery to the military or civilian market, incorporation into clinical practice, approval by a Regulatory Agency).
  - Ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award and the government’s ability to access such products or technologies in the future.
  - A risk analysis for cost, schedule, manufacturability and sustainability.
- **Attachment 12: Prior Outcomes Statement (if applicable; one-page limit): Upload as “Outcomes.pdf”. Attachment 12 will be available for programmatic review only.**  
If applicable, list all of the PI’s prior or in-progress CDMRP/PRMRP research projects/ awards including resulting publications, abstracts, patents, or other tangible outcomes. Only research and outcomes directly relevant to this application should be listed.
  - **Attachment 13: Representations (*Grants.gov submissions only*): Upload as “RequiredReps.pdf”. All extramural applicants must complete and submit the [Required Representations](#) document available on eBRAP.** 
  - **Attachment 14: Suggested Intragovernmental/Intramural Budget Form (*if applicable*): Upload as “IGBudget.pdf”. If an [intramural DOW organization](#) will be a collaborator in the performance of the project, complete a separate budget for that organization using the [Suggested Intragovernmental/Intramural Budget](#) form available on eBRAP.** 

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### (c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.



Grants.gov



eBRAP.org

---

#### i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

*Intragovernmental applicants must include their internally supported research and development programs.*

---

#### ii. Research & Related Budget

*Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Initiating PI should not include budget information for Partnering PI(s), or vice versa, even if they are located within the same organization. Refer to [Section 3.4, Funding Details](#), for detailed budget information.*

---

#### iii. Project/Performance Site Location(s)

---

**iv. Research & Related Subaward Budget Attachment(s)** *(if applicable, Grants.gov submissions only)*

---

### 4.3.2. Full Application Components for each Partnering PI

Refer to the equivalent attachment above for details specific to each of the following application components. See [Appendix 1](#) for a checklist of the full application components required for each Partnering PI.

(a) [SF424 Research & Related Application for Federal Assistance Form](#) (*Grants.gov Submissions Only*):

(b) **Attachments:**

- [Attachment 5: Statement of Work \(five-page limit\)](#): Upload as “SOW.pdf”. Each PI must submit an identical copy of a jointly created SOW.
- [Attachment 13: Representations \(Grants.gov submissions only\)](#): Upload as “RequiredReps.pdf”.
- [Attachment 14: Suggested Intragovernmental/Intramural Budget Form](#): Upload as “IGBudget.pdf”.

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### (c) [Additional Application Materials:](#)

The following are additional application materials for application submission. Follow the instructions specific to the submission portal found within the GAI.



Grants.gov



eBRAP.org

---

#### i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

*Intragovernmental applicants must include their internally supported research and development programs.*

---

#### ii. Research & Related Budget

*Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Partnering PI(s) should not include budget information for the Initiating PI, or vice versa, even if they are located within the same organization. Refer to [Section 3.4. Funding Details](#), for detailed budget information.*

---

#### iii. Project/Performance Site Location(s) Form

---

#### iv. Research & Related Subaward Budget Attachment(s) Form *(if applicable, Grants.gov submissions only)*

---

## 4.4. Other Application Elements

If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, [DoD Instructions 3200.12](#) will be requested.



The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

# 5. Submission Requirements

## 5.1. Location of Application Package

Download the application package components for HT942526PRMRPPCTA from [Grants.gov](#) or [eBRAP](#), depending on which submission portal will be used.


## 5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), [SAM.gov](#), and receive confirmation of an “Active” status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration. i

## 5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.

### *Application Submission Workflow*



### 5.3.1. Pre-Application Submission

All pre-application components must be submitted by the PI or Initiating PI through [eBRAP](#), including the submission of contact information for each Partnering PI if selecting the Partnering PI Option. i

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)  
 Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during [the full application submission process](#). The eBRAP log number, application title and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP. Contact the [eBRAP Help Desk](#) if any changes need to be made.

**Partnering PI Option:** After the Initiating PI confirms submission of the pre-application, the Partnering PI[(s)] will be notified of the pre-application submission via an email from eBRAP. ***The Partnering PIs must follow the instructions provided in the email to associate the partnering pre-application with their eBRAP account.*** If not previously registered, the Partnering PIs must register in eBRAP.

***Partnering PIs should not initiate a new pre-application based on the same research project submitted by the Initiating PI.*** Partnering PIs are urged to associate the partnering pre-application with their eBRAP account as soon as possible. If this is not completed by the full application deadline:

- Any intramural Partnering PI will not be able to submit their full application package components to eBRAP.
- The Partnering PIs will not be able to view and modify their full application during the verification period in eBRAP.

When starting the pre-application, PIs should select the Mechanism Option appropriate to their pre-application:

Application Includes:	Select Mechanism Option:
Single PI without a Clinical Trial	<b>Platform Clinical Translation Award</b>
Single PI with a Clinical Trial	<b>Platform Clinical Translation Award – Clinical Trial</b>
Partnering PI without a Clinical Trial	<b>Platform Clinical Translation Award – Partnering PI Option</b>
Partnering PI with a Clinical Trial	<b>Platform Clinical Translation Award – Clinical Trial – Partnering PI Option</b>

During the pre-application process, applicants will be asked to select the following:


- Select the FY26 PRMRP portfolio addressed by the proposed research. The portfolio selected should align to the primary topic area.
- Select the congressionally directed primary [FY26 PRMRP Topic Area](#) addressed by the proposed research.
- Select the FY26 PRMRP continuum of care category addressed by the proposed research.
- Select the [FY26 PRMRP Strategic Goal](#) addressed by the proposed research.
- Select the congressionally directed secondary [FY26 PRMRP Topic Area](#) addressed by the proposed research.

Changes to any of the above selections between the pre-application submission and full-application submission require an email to the [eBRAP Help Desk](#).

## Section Shortcuts


Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### 5.3.2. Full Application Submission

**Grants.gov Submissions:** Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace. 

**eBRAP Submissions:** Only [intramural DOW organizations](#) may submit full applications through eBRAP. 

### 5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application submission.   
***The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline.*** Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the [application verification period](#) ends. The full application cannot be modified once the application verification period ends.

### 5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant.***

Submission dates and times are specified in [Section 1, Basic Information](#).

### 5.5. Intergovernmental Review

Not applicable for this funding opportunity.

## Section Shortcuts


Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

# 6. Application Review Information

## 6.1. Application Compliance Review

***Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).***

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the [CDMRP's Directive on Research Duplication](#).

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns, may result in application withdrawal. 

Members of the FY26 PRMRP Programmatic Panel must not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members **may** provide [letters](#) to confirm [PI eligibility](#) and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). ***A list of the [FY26 PRMRP Programmatic Panel members](#) can be found on the CDMRP website.***

Additional restrictions and associated administrative responses are outlined in [Section 9.2, Administrative Actions](#).

## 6.2. Review Criteria

### 6.2.1. Pre-Application Screening Criteria

To determine the merits of the pre-application and the relevance to the mission of the Defense Health Program and the PRMRP, pre-applications will be screened based on the following criteria:

- **Impact and Platform Product:** How well the product under development addresses two of the congressionally directed [FY26 PRMRP Topic Areas](#) and one of the [FY26 PRMRP Strategic Goals](#). To what extent the product has the potential to transform clinical care for the patient populations relevant to the [FY26 PRMRP Topic Areas](#) addressed.
- **Research Strategy:** How well a hypothesis and specific aims are defined for each proposed project, and to what extent each project's approach will address them. How well the proposed projects advance the translational development of the platform product towards clinical implementation.
- **Relevance to Military Health:** To what degree the project is relevant to the health care needs of military Service Members, Veterans and/or beneficiaries.
- **Research Team:** To what degree the background, expertise, and commitment of the PI(s) and key personnel are appropriate with respect to their abilities to successfully complete the projects; and the extent to which the PI(s) is/are well prepared and committed to lead the research team and proposed projects. If the partnering option is selected, to what degree

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

the expertise of the partners is complementary and to what extent the team has demonstrated a strategy to ensure synergy.

### 6.2.2. Peer Review Criteria

To determine technical merit, all applications will be evaluated individually according to the following **scored criteria**, which are listed in decreasing order of importance:

#### **Scored review criteria for all applications:**

- **Impact**

- To what extent the proposed project aligns to the two applicant-selected [FY26 PRMRP Topic Areas](#).
- To what extent the project address a critical problem or question aligned to both of the applicant-selected congressionally directed [FY26 PRMRP Topic Areas](#).
- To what extent the proposed research project addresses the PI-selected [FY26 PRMRP Portfolio-Specific Strategic Goal](#).
- To what degree the proposed platform product will make a significant impact on the lives of the proposed patient populations in the short term.
- If applicable, to what extent the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.

- **Research Strategy and Feasibility**

- How well the scientific rationale supports the research and its feasibility, as demonstrated by a critical review and analysis of the literature, the presentation of preliminary data (where applicable), and logical reasoning.
- To what extent the preliminary data that supports development of the platform product has already been initiated by the study team, has passed the initial discovery stage, and has near-term potential for clinical translation.
- How well the hypotheses and objectives, experimental design, and methods have been developed; and how well they support completion of the necessary milestones.
- How well studies are designed to achieve reproducible and rigorous results, including the choice of model, statistical methodology and plan, power analysis, and the endpoints/outcomes to be measured.
- If applicable, whether the strategy for the inclusion of women and minorities and the distribution of proposed enrollment are appropriate for the proposed research.
- Whether there is sufficient evidence to support availability and accessibility of the populations, samples, or other resources required for the study, if applicable.
- How well potential problems are acknowledged and alternative approaches are addressed.
- Whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study or whether the justification for a single-sex study is sufficiently strong.
- To what extent the plan for sharing of project data and research resources is appropriate and reasonable and includes dissemination to affected communities, study participants

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

and/or the scientific community. If applicable, whether specific repository(ies) are named where data and research resources arising from the project will be stored.

### • Implementation Plan

- How well the proposed project(s) is/are supported by a detailed implementation plan that identifies critical milestones and explains how these milestones will be achieved.
- To what extent the plans to assess performance and progress during the course of the award are appropriate.
- How well the overall management plan will facilitate consistent and intensive interactions and communication by all team members.
- How the proposed plans for communication, data and specimen collection, data transfer, and periodic meetings are appropriate.
- To what degree the scientific environment is appropriate for the proposed research.
- How well the research requirements are supported by the availability of and accessibility to facilities and resources (including patient populations, samples, and collaborative arrangements).
- To what degree the quality and extent of organizational support are appropriate for the proposed research.

### • Post-Award Transition Plan

- To what extent the anticipated outcomes will support the translation of promising preclinical findings to the next stage of development (clinical trials, commercialization, and/or delivery to the civilian or military market) after successful completion of the award.
- If applicable, whether data will be appropriately reported and documented to support a regulatory filing with the FDA.
- Whether the identified post-award steps for development and/or plans for commercialization are realistic.
- Whether the funding strategy described bringing the product to the next level of development (e.g., specific potential industry partners, specific funding opportunities to be applied for) is reasonable and realistic.
- Whether the regulatory strategy and the development plan to support the proposed product label, if applicable, are appropriate and well-described.
- If applicable, whether the proposed collaborations and other resources for providing continuity of development of knowledge products (including proposed development or modification of clinical practice guidelines and recommendations, provider training materials, patient brochures) and other clinical support tools, scientific journal publications, models, simulations, and applications are established and/or achievable.
- Whether the schedule and milestones for bringing the anticipated product to the next phase of development through to achieving a clinically meaningful outcome (clinical trials, transition to industry, delivery to the military or civilian market, incorporation into clinical practice, or approval by the FDA) are achievable. Whether the potential risk analysis for cost, schedule, manufacturability, and sustainability is realistic and reasonable.
- If applicable, to what degree the intellectual and material property plan is appropriate.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- **Budget**
  - To what extent the proposed budget is adequately justified and reflects the proposed research.
- **Personnel and Communication**
  - To what degree the composition of the study team, including any external consultants or advisors (e.g., statistician, regulatory expert, commercialization consultant, clinical ethicist, patient advocate), is appropriate to accomplish the proposed work.
  - Whether the levels of effort of the study team members are appropriate for successful conduct of the proposed trial.
  - How well the logistical aspects of the study team (e.g., communication plan, data transfer and management, standardization of procedures, multi-institutional structure governing the research protocol[s]) are appropriate and meet the needs of the proposed project(s).
  - To what extent the members of the advisory board, including the mandatory patient advocate, will play an integral role in the planning, design, implementation, and evaluation of the research.
  - If applicable, whether the inclusion of any personnel working at international sites is adequately justified.
  - **Partnering PI Option:** How the partners' combined expertise will better address the research question.

### ***Additional criteria for applications proposing clinical trials only:***

- **Clinical Impact: The criteria below will be weighted directly below the Impact criterion that are applicable to all applications.**
  - How well the sample population represents the targeted patient population that might benefit from the proposed intervention.
  - How the potential outcomes of the proposed clinical trial will provide/improve short-term benefits for individuals.
  - To what degree the long-term benefits for implementation of the intervention may impact patient care and/or quality of life.
  - To what degree the intervention addresses current clinical need(s); improves upon available interventions and/or standards of care; or addresses controversies, treatment issues or health disparities within the field.
- **Research Strategy and Feasibility: The criteria below will be added to the Research Strategy and Feasibility criterion that are applicable to all applications.**
  - How well the scientific rationale for the proposed clinical trial is supported by the review and analysis of the available literature and completed/ongoing studies.
  - To what degree the application includes preclinical and/or clinical evidence to support the safety and stability (as appropriate) of the intervention; or, to what degree the application includes a plan to generate this evidence prior to initiation of the trial.
  - Whether there is evidence of support, indicating availability of the intervention from its source, for the duration of the proposed clinical trial (if applicable).

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- How well the specific aims/hypotheses/research question, study design, experimental methods, data collection procedures and evaluations are designed to address the clinical objective and purpose of the study.
- How well the studies are designed to achieve reproducible and rigorous results, including the endpoints/outcomes to be measured.
- If applicable, whether the strategy for the inclusion of women and minorities and the distribution of proposed enrollment are appropriate for the proposed research.
- To what degree the statistical plan and power analysis, including sample size projections, are appropriate for the proposed project and will allow for a meaningful outcome.
- If applicable, whether measures are described to ensure the consistency of dosing (e.g., active ingredients for nutritional supplements, rehabilitation interventions).
- Whether there is sufficient evidence to support the availability and accessibility of the populations, samples, or other resources required for the study, if applicable.
- How well potential problems are acknowledged and alternative approaches are addressed.
- **Regulatory Strategy: The criteria below will be added and weighted directly below Research Strategy and Feasibility.**
  - How the regulatory strategy and development plan to support the product indication or product label change, if applicable, are appropriate and well described.
  - Whether the application includes documentation that the study is exempt from regulatory agency oversight, or that the IND or IDE application (and/or international equivalent) has been submitted to the Regulatory Agency, as appropriate.
  - How well the documentation provided supports the feasibility of acquiring an active IND or IDE (and/or international equivalent) covering the proposed trial, if applicable.
  - For investigator-sponsored regulatory exemptions (e.g., IND, IDE, or other international equivalent), whether there is evidence of appropriate institutional support.
  - Whether plans to comply with GMP, GLP, and GCP guidelines are appropriate.
- **Recruitment and Accrual: The criteria below will be added and weighted directly below the Regulatory Strategy.**
  - To what degree the plan for recruiting, enrolling, and retaining study participants is reasonable to meet the needs of the proposed clinical trial.
  - How well the application identifies possible delays (e.g., slow/low enrollment, poor retention) and presents adequate mitigation plans to resolve them.
  - To what degree the number of study participants to be enrolled is reasonable based upon the proposed timeline, study procedures, available study population, inclusion and exclusion criteria, and planned efforts to achieve accrual goals.
  - If applicable, to what degree barriers to clinical trial participation have been considered and/or addressed.
  - Whether the distribution of the proposed enrollment on the basis of age, sex, race, and/or ethnicity is appropriate for the proposed research.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- If applicable, whether the justification for limiting inclusion of any demographic group, including sex, is sufficiently strong.
- To what extent the strategy for recruitment and retention of women and minorities in the clinical trial is appropriate to the objectives of the study.
- **Ethical Considerations: The criteria below will be added and weighted directly below Recruitment and Accrual.**
  - Whether the population selected to participate in the trial stands to benefit from the knowledge gained.
  - How the level of risk to human participants is minimized, and how the safety monitoring and reporting plan is appropriate for the level of risk.
  - To what degree the process of seeking informed consent is appropriate and whether safeguards are in place for vulnerable populations.
  - To what extent the proposed clinical trial might affect the daily lives of the individual human participants participating in the study.
  - To what degree privacy and confidentiality issues are appropriately considered.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria**:

- **Environment**
  - To what extent the scientific environment and level of institutional support are appropriate for the proposed research project.
  - How well the research requirements are supported by the availability of and accessibility to facilities and resources.
- **Application Presentation**
  - To what extent the writing, clarity and presentation of the application components influence the review.

### 6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 PRMRP, as evidenced by the following:
  - Adherence to the intent of the funding opportunity
  - Relative impact
  - Relevance to the congressionally directed [FY26 PRMRP Topic Areas](#)
  - Relevance to the [FY26 PRMRP Strategic Goals](#)
  - Relevance to military health

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- Program portfolio composition
- Relative outcomes from the PI's previous CDMRP-/PRMRP-funded research (if applicable)

### 6.3. Application Review and Selection Process

#### 6.3.1. Pre-Application

Following the pre-application screening, PIs or Initiating PIs will be notified as to whether they are invited to submit full applications. The estimated date when PIs can expect to receive notification of an invitation to submit a full application is indicated in [Section 1, Basic Information about the Funding Opportunity](#). No feedback (e.g., a critique of the pre-application's strengths and weaknesses) is provided at this stage. Because the invitation to submit a full application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

#### 6.3.2. Full Application

All applications are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are subject to review and approval by a designated official. ***The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in [Section 6.2.3, Programmatic Review](#).*** Additional information about the two-tier process used by the CDMRP can be found on the [CDMRP website](#).

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a [limited time period](#) based on the fiscal year of the funds.

### 6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in the Code of Federal Regulations, Title 2, Part 200.1 (2 CFR 200.1), over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the SAM.

An applicant organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities.

## Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)  
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the [DOD Component Decision Matrix](#) must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | [Federal Award Notices](#) | Post-Award Requirements | Other Information


## 7. Federal Award Notices

For each compliant full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the PRMRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable [database](#).

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

***Only an appointed DHACA Grants Officer may obligate the government to the expenditure of funds to an extramural organization.*** No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

***Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.***

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official. 

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | [Post-Award Requirements](#) | Other Information

# 8. Post-Award Requirements


## 8.1. Administrative and National Policy Requirements


Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

The GAI contain information regarding [administrative requirements](#) and [national policy requirements](#).

Refer to full text of the latest [DoD R&D Terms and Conditions](#) and the [DHACA Terms and Conditions](#) for further information.

***If there are delinquencies in technical reporting requirements for any existing DHA or U.S. Army Medical Research and Development Command awards at the applicant organization, DHACA will not issue any new awards to the applicant organization until all delinquent reports have been submitted.***

Funded trials are required to post a copy of the informed consent form used to enroll subjects on a publicly available federal website in accordance with federal requirements described in 32 CFR 219. Additionally, the CDMRP requires all funded clinical trials to register and submit study results on [ClinicalTrials.gov](#). 

Applications recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D Office of Research and Regulatory Compliance (ORRC), prior to implementation. This administrative review requirement is in addition to the local IACUC, IRB or Ethics Committee (EC) review. 

## 8.2. Reporting

Annual technical progress reports as well as a final technical progress report will be required. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

PHS Inclusion Enrollment Reporting (***required for research proposing [clinical research and/or clinical trials](#)***): Enrollment reporting on the basis of sex, race, and/or ethnicity will be required with each annual and final progress report. The [PHS Inclusion Enrollment Report](#) is available on eBRAP.

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

For applications proposing a clinical trial Quarterly and Annual Technical Reports, as well as a final technical report, will be required. Technical reports must be prepared in accordance with the RPPR.

Award Expiration Transition Plan: An [Award Expiration Transition Plan](#), using the template available on eBRAP, must be submitted with the final progress report.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than

## Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)  
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

\$10M are required to provide information to the SAM about certain civil, criminal and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable [Representations](#).

### 8.3. Additional Requirements

PI(s) may be required to present their progress toward accomplishing research milestones and project goals at a Milestone Meeting. The Milestone Meeting will be held virtually at the discretion of the government.

An organizational transfer of an award supporting the Initiating PI or Partnering PI is discouraged and will be evaluated on a case-by-case basis.

The organizational transfer of an award supporting a clinical trial is strongly discouraged and, in most cases, will not be allowed. Approval of a transfer request will be on a case-by-case basis.

Unless otherwise restricted, changes in the PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.



An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | [Other Information](#)

# 9. Other Information

## 9.1. Program Announcement Version

Questions related to this program announcement should refer to the program name, the program announcement name and the program announcement version code CD26\_01d.

## 9.2. Administrative Actions

After receipt of pre-applications and full applications, the following administrative actions may occur.

### 9.2.1. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative exceeds page limit.
- Preproposal Narrative is missing.

The following will result in administrative rejection of the full application:

- The Project Narrative is missing.
- The Budget is missing.
- Submission of an application for which a letter of invitation was not issued.
- The Project Narrative exceeds page limit.

### 9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

### 9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the FY26 PRMRP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- The application includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the [CDMRP website](#).
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application from an extramural organization, including non-DOW federal agencies, is received through eBRAP.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | [Other Information](#)

- The federal government recipient organization (including an intramural DOW organization):  
(a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b) cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.
- The application fails to conform to this program announcement description.
- The application includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- The same research project is submitted to different funding opportunities within the same program and fiscal year.
- The application fails to address at least two of the congressionally directed [FY26 PRMRP Topic Areas](#).
- The application fails to address one of the [FY26 PRMRP Strategic Goals](#).
- The investigator is named as Initiating PI on more than one application submitted to the FY26 PRMRP. If more than one pre-application is submitted naming the same Initiating PI to the FY26 PRMRP, then the first submission will be accepted and the remaining will be administratively withdrawn.
- The PI does not meet the [eligibility criteria](#).
- The invited application proposes a different research project than that described in the pre-application.
- Failure to submit all associated (Initiating and Partnering PI) applications by the deadline.

### 9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Grants Officer for a determination of the final disposition of the application.

### 9.2.5. Other Funding Opportunities

The PRMRP is committed to leveraging efforts with other funding organizations to accelerate progress in research. At the time of funding notifications, the PRMRP may inform highly rated, unfunded applicants about opportunities to provide their PRMRP applications and peer review summary statements to non-governmental and other governmental funders, who will determine the specific criteria for funding consideration.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

# Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded	
	PI/Initiating PI	Partnering PI
<b>SF424 Research &amp; Related Application for Federal Assistance</b> <i>(Grants.gov submissions only)</i>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Summary (Tab 1) and Application Contacts (Tab 2)</b> <i>(eBRAP submissions only)</i>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Attachments</b>		
<a href="#">Project Narrative</a> – Attachment 1, upload as “ProjectNarrative.pdf”	<input type="checkbox"/>	
<a href="#">Supporting Documentation</a> – Attachment 2, upload as “Support.pdf”	<input type="checkbox"/>	
<a href="#">Technical Abstract</a> – Attachment 3, upload as “TechAbs.pdf”	<input type="checkbox"/>	
<a href="#">Lay Abstract</a> – Attachment 4, upload as “LayAbs.pdf”	<input type="checkbox"/>	
<a href="#">Statement of Work</a> – Attachment 5, upload as “SOW.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
<a href="#">Impact Statement</a> – Attachment 6, upload as “Impact.pdf”	<input type="checkbox"/>	
<a href="#">Relevance to Military Health Statement</a> – Attachment 7, upload as “MilRel.pdf”		
<a href="#">Clinical Strategy and Recruitment Statements</a> <i>(if applicable)</i> – Attachment 8, upload as “Clinical.pdf”	<input type="checkbox"/>	
<a href="#">Animal Research Plan</a> <i>(if applicable)</i> – Attachment 9, upload as “AnimalResPlan.pdf”	<input type="checkbox"/>	
<a href="#">Partnership Statement</a> <i>(if applicable)</i> – Attachment 10, upload as “Partnership.pdf”	<input type="checkbox"/>	
<a href="#">Post-Award Transition Plan</a> – Attachment 11, upload as “Transition.pdf”	<input type="checkbox"/>	
<a href="#">Prior Outcomes Statement</a> <i>(if applicable)</i> – Attachment 12, upload as “Outcomes.pdf”	<input type="checkbox"/>	
<a href="#">Representations</a> <i>(Grants.gov submissions only)</i> – Attachment 13, upload as “RequiredReps.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
<a href="#">Suggested Intragovernmental Budget Form</a> <i>(if applicable)</i> – Attachment 14, upload as “IGBudget.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
<b><a href="#">Additional Application Materials</a></b>		
<b>Research &amp; Related Senior/Key Person Profile (Expanded)</b>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Attach Biographical Sketch for Senior/Key Persons</b> <b>(Biosketch_LastName.pdf)</b>	<input type="checkbox"/>	<input type="checkbox"/>

### Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)  
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

---

<b>Attach Current/Pending Support for Senior/Key Persons (Support_LastName.pdf)</b>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Research &amp; Related Budget</b>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Project/Performance Site Location(s)</b>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Research &amp; Related Subaward Budget Attachment(s) (<i>if applicable</i>)</b>	<input type="checkbox"/>	<input type="checkbox"/>

---

## Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)  
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

## Appendix 2. Acronym List

ARRIVE	Animal Research: Reporting of In Vivo Experiments
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
CONSORT	Consolidated Standards of Reporting Trials
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHACA	Defense Health Agency Contracting Activity
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	U.S. Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FDA	U.S. Food and Drug Administration
FY	Fiscal Year
GAI	General Application Instructions
GCP	Good Clinical Practices
GLP	Good Laboratory Practices
GMP	Good Manufacturing Practices
IACUC	Institutional Animal Care and Use Committee
IDE	Investigational Device Exemption
IND	Investigational New Drug
IRB	Institutional Review Board
LAR	Legally Authorized Representative
M	Million
MIPR	Military Interdepartmental Purchase Request
ORRC	Office of Research and Regulatory Compliance
PANDAS	Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus
PANS	Pediatric Acute-Onset Neuropsychiatric Syndrome
PDF	Portable Document Format
PHS	Public Health Service

### Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)  
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

PI	Principal Investigator
PCTA	Platform Clinical Translation Award
PRMRP	Peer Reviewed Medical Research Program
R&D	Research and Development
RPPR	Research Performance Progress Report
SAM	System for Award Management
SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)
SOW	Statement of Work
SPIRIT	Standard Protocol Items: Recommendations for Interventional Trials
STROBE	STrengthening the Reporting of OBservational studies in Epidemiology
UEI	Unique Entity Identifier
URL	Uniform Resource Locator
USC	United States Code
VA	U.S. Department of Veterans Affairs